breast cancer oncotype score

Release time ：Nov-11,2024

Breast cancer gene expression profiling is a molecular diagnostic technique employed to evaluate the risk of recurrence and the potential response to chemotherapy in breast cancer patients. This method forecasts patient outcomes by assessing the expression levels of 21 genes within breast cancer tissue samples.

Typically, the scores from breast cancer gene expression profiling range from 0 to 100, with higher scores suggesting a higher risk of recurrence and potentially a better response to chemotherapy. Patients scoring below 11 are generally classified as low risk and may not require chemotherapy; those with scores between 11 and 25 are considered medium risk, and physicians might consider chemotherapy based on individual circumstances; whereas patients with scores above 25 are deemed high risk and often undergo chemotherapy to mitigate the risk of recurrence.

Understanding one's gene expression profile is crucial for breast cancer patients as it aids in the development of more tailored treatment plans. However, it is important to recognize that this profile is not the sole determinant; physicians also consider factors such as the patient's age, tumor dimensions, and lymph node involvement for a holistic assessment. Consequently, patients should adhere to their doctor's recommendations and not independently decide on chemotherapy or other treatment options. Additionally, maintaining healthy lifestyle habits and engaging in regular health check-ups are vital for the prevention of breast cancer recurrence.